Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021
The study “Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021” provides a comprehensive analysis of Long COVID’s prevalence and characteristics.
Here’s a detailed summary:
Study Objective and Importance: The study aimed to estimate the prevalence of Long COVID symptoms in individuals who had COVID-19. Long COVID refers to persistent symptoms experienced after the initial symptomatic phase of SARS-CoV-2 infection.
Methodology: The study utilized Bayesian meta-regression and pooled data from 54 studies and two medical record databases, covering 1.2 million individuals from 22 countries. The data spanned from March 2020 to January 2022.
Main Outcomes: The study focused on three Long COVID symptom clusters: persistent fatigue with bodily pain or mood swings, cognitive problems, and ongoing respiratory problems, assessed three months post-infection.
Results: 6.2% of individuals with symptomatic SARS-CoV-2 infection developed at least one Long COVID symptom cluster. Specific prevalence rates were 3.2% for persistent fatigue with bodily pain or mood swings, 3.7% for ongoing respiratory problems, and 2.2% for cognitive problems. Women aged 20 years or older experienced Long COVID symptoms more frequently (10.6%) than men of the same age group (5.4%). The prevalence was lower (2.8%) in individuals younger than 20 years. The average duration of Long COVID symptoms was nine months for hospitalized individuals and four months for non-hospitalized individuals.
Hospitalization and ICU Care: The risk of developing Long COVID was significantly higher in individuals who required hospitalization, especially those needing ICU care. ICU-admitted patients had a 43.1% risk, and those admitted to general wards had a 27.5% risk, compared to a 5.7% risk in non-hospitalized individuals.
Duration of Symptoms: Hospitalized individuals experienced Long COVID symptoms for an average of nine months, while non-hospitalized individuals experienced symptoms for an average of four months.
Gender Differences: The study highlighted a higher prevalence of Long COVID among females (63.2%) globally, with women showing a greater risk than men.
Age Factor: Younger individuals (under 20 years) had a lower risk of Long COVID (2.7%) compared to adults, with women experiencing higher rates than men in the older age group.
Long-Term Persistence: Approximately 15.1% of individuals with Long COVID symptoms three months post-infection continued to experience symptoms at 12 months.
Pathology and Implications: The study underscores the need for healthcare services to support Long COVID patients towards recovery and return to normal life. It notes the lack of clear pathology for Long COVID, suggesting a complex interplay of immune response, coagulation, and autonomic dysregulation.
Limitations: The study acknowledges limitations such as wide uncertainty intervals, varying methodologies across studies, and assumptions about the uniformity of Long COVID’s course across different regions. It also focused only on three symptom clusters, potentially overlooking other common Long COVID symptoms.
In summary, this study provides valuable insights into the prevalence, characteristics, and impact of Long COVID globally. It highlights the condition’s significant burden, particularly among women and hospitalized individuals, and underscores the need for continued research and healthcare support for affected individuals.